Aspira Pathlab & Diagnostics (BSE: ASPIRA) is loss-making over the last 12 months, losing ₹0.41 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹133.60, 11% below its 52-week high. Sales grew 20% a year over 3 years. Debt is 0.27× equity. It is a small-cap company with a market cap of ₹138 Cr, ranked 13th of 18 Diagnostics & Research companies by market cap; the shares rose 130% over the past year.
- ₹138.00
- ₹141.70
- ₹131.90
- ₹138.80
- 1.3K
Health check
- ReturnsAhead
+130.1% over a year, better than 7 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +20.0% a year over 3 years, but loss-making now.
- ProfitabilityWeak
ROCE 2.5% vs peer median 19.1%.
- Balance sheetStretched
Debt 0.27× equity, interest covered 1.2×, Piotroski 5 of 9.
- Red flags3 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹138 Cr
- Small cap
- P/E
- n/a
- Industry 52.8
- Price to book
- 11.23
- Peers 11.99
- Dividend yield
- 0.00%
- ROE
- 0.7%
- Peers 17.7%
- ROCE
- 2.5%
- Peers 19.1%
- Debt to equity
- 0.27
- Debt ₹3.32 Cr
- EPS (TTM)
- −₹0.45
- OPM (TTM)
- 3.8%
- Net margin −1.6%
- Sales growth
- +17.6%
- Latest quarter vs a year ago
- Profit growth
- −108.0%
- Latest quarter vs a year ago
- Price to sales
- 5.31
- EV/EBITDA 133.8
Strengths and risks
Strengths
- Quarterly sales up 17.6% on a year ago.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at 0.7%.
- Quarterly profit down 108.0% on a year ago.
About Aspira Pathlab & Diagnostics
Aspira Pathlab & Diagnostics Limited owns, manages, runs, and administers various diagnostics centers primarily in India. The company offers biochemistry, hematology, histopathology, microbiology, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigation services. It also provides pathology, sonography, x-ray, and radiology tests. The company was formerly known as Utkal Soap Products Limited and changed its…
- Headquarters
- Mumbai
- Employees
- 168
- Sector
- Healthcare
- ISIN
- INE500C01017
- Website
- aspiradiagnostics.com
Price range
- Avg volume (3M)
- 1.4K
- 1-year return
- plus 130.1%
- From 52-week high
- minus 10.9%
Peers · Diagnostics & Research
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAILIFESai Life Sciences | 1,785.10 | plus 11.95% | 37,929 | 101.5 | 15.22 | 18.1% | 15.1% | 28.7% | 21.3% | 226.8% | 0.00% | plus 72.7% |
| LALPATHLABDr. Lal Path Labs | 1,970.00 | plus 0.16% | 32,941 | 56.5 | 11.99 | 25.7% | 22.6% | 30.2% | 11.1% | 28.3% | 1.02% | plus 24.7% |
| SYNGENESyngene International | 417.30 | plus 0.77% | 16,772 | 90.3 | 3.46 | 8.3% | 3.9% | 25.7% | 5.4% | −12.0% | 0.30% | minus 36.0% |
| VIJAYAVijaya Diagnostic Centre | 1,468.60 | plus 2.15% | 15,126 | 74.4 | 14.29 | 19.1% | 21.2% | 43.1% | 21.0% | 26.9% | 0.14% | plus 40.2% |
| METROPOLISMetropolis Healthcare | 568.75 | minus 0.39% | 11,803 | 52.8 | 7.17 | 15.7% | 14.6% | 21.7% | 12.7% | 10.0% | 0.35% | plus 12.5% |
| THYROCAREThyrocare Technologies | 493.10 | plus 0.68% | 7,848 | 55.0 | 14.75 | 33.8% | 26.4% | 32.2% | 16.7% | 36.2% | 1.89% | plus 8.3% |
| VIMTALABSVimta Labs | 496.45 | minus 2.14% | 2,219 | 27.9 | 4.52 | 21.0% | 17.7% | 34.7% | 8.9% | 17.2% | 0.40% | minus 23.3% |
| ASPIRAAspira Pathlab & Diagnostics | 133.60 | minus 3.75% | 138 | – | 11.23 | 2.5% | 0.7% | 3.8% | 20.0% | – | 0.00% | plus 130.1% |
| Median of 7 peers | – | 0.68% | 15,126 | 56.5 | 11.99 | 19.1% | 17.7% | 30.2% | 12.7% | 26.9% | 0.35% | 12.5% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 5.2 | 8.1 | 5.1 | 6.5 | 6.2 | |
| 4.4 | 5.9 | 6.3 | 6.9 | 5.8 | |
| 0.8 | 2.2 | −1.2 | −0.3 | 0.3 | |
| 15.6% | 27.0% | −23.6% | −5.1% | 5.6% | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | |
| 0.5 | 1.8 | −1.6 | −0.7 | −0 | |
| 0.5 | 1.8 | −1.6 | −0.7 | −0 | |
| 0.46 | 1.78 | -1.52 | -0.67 | -0.04 |
Profit & loss
- Sales CAGR 3Y
- +20.0%
- ROE
- 0.7%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 14.5 | 13.2 | 22 | 25 | |
| – | minus 8.7% | +66.6% | +13.6% | |
| 12.9 | 14.4 | 18.4 | 23.5 | |
| 1.6 | −1.2 | 3.6 | 1.5 | |
| 11.1% | −8.8% | 16.2% | 6.1% | |
| 0.3 | 0.4 | 0.3 | 0.5 | |
| 0.4 | 0.3 | 0.3 | 0.3 | |
| 1.6 | 1.5 | 1.5 | 1.5 | |
| 0 | −0 | −0 | −0.1 | |
| −0.1 | −2.7 | 2.1 | 0.1 | |
| −0.1 | −2.7 | 2.1 | 0.1 | |
| -0.09 | -2.60 | 2.01 | 0.05 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 15.2 | 15.2 | 15.2 | 15.2 | |
| −7.4 | −10 | −7.9 | −7.9 | |
| 2.4 | 1.7 | 2 | 2 | |
| 7.2 | 7.8 | 8.2 | 9.2 | |
| 17.3 | 14.7 | 17.5 | 18.5 | |
| 5.3 | 4.1 | 3.9 | 3.9 | |
| 0.4 | 0.3 | 1.8 | 2.8 | |
| 2.3 | 1.4 | 2.1 | 1.7 | |
| 9.3 | 8.9 | 9.7 | 10.2 | |
| 17.3 | 14.7 | 17.5 | 18.5 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −0 | 1.1 | 1.9 | 1.5 | |
| 0.2 | 0.1 | 0.1 | −0.8 | |
| −0.9 | −1 | −1 | −1.1 | |
| −0.8 | 0.2 | 0.9 | −0.5 | |
| −0.1 | −0.3 | −0.3 | −0.7 | |
| −0.1 | 0.8 | 1.5 | 0.8 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.